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Edited by Irmgard SinningAbstract The X-ray crystal structure of the copper-containing
quinoprotein amine oxidase from E. coli has been determined in
complex with the antidepressant drug tranylcypromine to 2.4 A
resolution. The drug is a racemic mix of two enantiomers, but
only one is seen bound to the enzyme. The other enantiomer is
not acting as a substrate for the enzyme as no catalytic activity
was detected when the enzyme was initially exposed to the drug.
The inhibition of human copper amine oxidases could be a source
of side-eﬀects in its use as an antidepressant to inhibit the ﬂavin-
containing monoamine oxidases in the brain.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tranylcypromine (TCP) is used in the treatment of depres-
sion (brand name, Parnate (SmithKline Beecham)). TCP
belongs to the class of antidepressants that inhibit the ﬂavin-
containing monoamine oxidases found in the brain (MAOIs).
These drugs have been used clinically for over 30 years, along
with the tricyclic antidepressants (TCAs). Multiple side-eﬀects
have been recorded, and this led to the development of new
classes of antidepressants, for example the serotonin reuptake
inhibitors [1]. However, these new drugs are less eﬀective and
many people who do not respond to the newer drugs can be
successfully treated with MAOIs or TCAs. TCP is therefore
still used to treat major depression in patients where the side-
eﬀects can be closely supervised.* Corresponding authors. Present address: Department of Biochemi-
stry, Molecular Biology and Biophysics, University of Minnesota, 6-155
Jackson Hall, 321 Church St. SE, Minneapolis, MN 55455, USA.
Fax: +1-612-624-5121 (C.M. Wilmot); +44-113-343-1407 (S.E.V.
Phillips).
E-mail addresses: wilmo004@umn.edu (C.M. Wilmot),
s.e.v.phillips@leeds.ac.uk (S.E.V. Phillips).
Abbreviations: TCP, tranylcypromine; MAOI, ﬂavin-containing mono-
amine oxidase inhibitor; TCA, tricyclic antidepressant; CuAO, copper-
containing amine oxidase; HuPAO, human plasma amine oxidase;
AGE, advanced glycation endproduct; TPQ, 2,4,5-trihydroxyphenyl-
alanine quinone; ECAO, Escherichia coli amine oxidase; 2-HP,
2-hydrazinopyridine
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doi:10.1016/j.febslet.2004.09.031TCP is a reversible inhibitor of the ﬂavin monoamine ox-
idases, and is administered as a racemic mixture of the two
trans enantiomers, 1S,2R-(+)-trans-2-phenylcyclopropylamine
((+)-TCP) and 1R,2S-())-trans-2-phenylcyclopropylamine
(())-TCP) (Fig. 1(a)) [2]. Diﬀerences in the eﬃcacy and side-
eﬀects of administering the two enantiomers separately have
been reported, with (+)-TCP being ten times more potent a
MAOI, and ())-TCP exhibiting a 3–4 times greater inhibition
of catecholamine uptake [3,4]. The racemic TCP has also been
shown to inhibit the copper-containing amine oxidases (Cu-
AOs), for which there are three homologues in human tissues
[5]. Interest in inhibitors of CuAOs has increased recently due
to the observation that the elevated levels of human plasma
amine oxidase (HuPAO) observed in diabetes mellitus patients
[6] correlate to the degree of late-diabetic vascular disease [7,8].
Aldehydes resulting from HuPAO activity lead to advanced
glycation endproducts (AGEs) [9], the major cause of late-di-
abetic complications, including neuropathy, nephropathy and
retinopathy [10,11]. Additionally, the hydrogen peroxide pro-
duced during CuAO catalysis may enhance oxidative damage
[12] and play a role in vasoconstriction [13]. However, the true
physiological roles and substrates of the human CuAOs
remain elusive.
The CuAOs catalyse the conversion of primary amines to
aldehydes in an aerobic redox reaction involving both the
copper ion and a quinone cofactor (TPQ) formed by post-
translational modiﬁcation of a constituent tyrosine residue
(Fig. 1(b)) [14]. The catalytic mechanism of the enzyme has
been extensively studied kinetically and spectroscopically [15],
and through X-ray crystallography of the Escherichia coli
enzyme (ECAO) [16–19]. During catalysis the amine substrate
forms a Schiﬀ base with the TPQ (Fig. 1(b)), and a proton is
abstracted from the methylene carbon bonded to the primary
amine group by a conserved aspartate base in the enzyme.
This abstraction is stereospeciﬁc, but varies with enzyme
source [20]. ECAO always abstracts the pro-S proton from its
preferred substrates, aromatic monoamines [17]. The much
studied irreversible hydrazine derivative inhibitors of CuAOs
trap the enzyme in a covalent adduct analogous to the Schiﬀ
base intermediate of the reaction [14]. The 2.0A X-ray crystal
structure of ECAO complexed with 2-hydrazinopyridine
(2-HP) showed the TPQ cofactor covalently linked to 2-HP
via position 5 of its ring (Fig. 2) [17]. The 2-HP moiety lay
next to Asp 383, the catalytic base of the reaction, with the
pyridine ring directed away from the copper ion. The TPQ is
indirectly linked to the copper ion via a hydrogen bondblished by Elsevier B.V. All rights reserved.
Fig. 2. Comparison of the active site of the (+)-TCP complex (carbon atoms yellow) and the 2-HP complex (carbon atoms green and purple; waters
green). Residues in the peripheral domain (D3) that forms part of the substrate entry channel are indicated by boxed residue identiﬁers, whilst those
of the catalytic domain (D4) are unboxed. Figure produced using SPOCK [39].
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Fig. 1. (a) The trans enantiomers of TCP; 1S,2R-(+)-trans-2-phenylcyclopropylamine ((+)-TCP) and 1R,2S-())-trans-2-phenylcyclopropylamine (())-
TCP). (b) Comparison of covalent adducts of TPQ. The substrate Schiﬀ base adduct with the ECAO substrate, b-phenylethylamine is shown with the
inhibitor adducts formed with TCP and 2-HP, an example of a hydrazine based inhibitor. Labelling of atoms corresponds to the text, except for HS
and HR which correspond to the pro-S and pro-R protons, respectively.
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nated to the copper. The copper ion appears sensitive to the
state of the quinone, as the equatorial water ligand (We) in-
creases its distance from the copper by 1.0 A in the 2-HP
complex compared to the native ECAO structure. Unlike
substrate, these hydrazine based inhibitors have a nitrogen
adjacent to the primary amine group, and the enzyme is un-
able to catalyse the chemistry required to break the N–N
bond to release a product. In this respect, TCP resembles
substrate in having a carbon atom attached to the amine
group, but it is a tertiary rather than a secondary carbon with
only one proton (Fig. 1(b)). The inhibitory eﬀects of TCP on
copper amine oxidases in solution studies have been reported
recently [21,22]. The diﬀering stereospeciﬁcity of CuAOs in
mammals could potentially lead to diﬀerential binding of the
two enantiomers of TCP and could contribute to the enan-
tiomeric speciﬁc side-eﬀects in treating depression. To inves-
tigate whether binding of TCP to an amine oxidase is
stereospeciﬁc and to examine the inhibitory action of this
drug on a CuAO, we have determined the X-ray crystal
structure of ECAO following exposure to racemic TCP.2. Materials and methods
2.1. Enzyme activity
ECAO protein was prepared as detailed previously [16]. Enzyme
activity was assayed by measuring oxygen consumption during catal-
ysis using an oxygen electrode (Rank Brothers). The baseline for the
reaction was the enzyme buﬀer; air saturated 100 mM phosphate
buﬀer, pH 7.0. ECAO was added to the reaction mix (2.5 mM racemic
TCP in air saturated 100 mM phosphate buﬀer, pH 7.0) to a ﬁnal
concentration of 0.035 mg/ml. Monitoring continued for 60 min with
no evidence of oxygen consumption. The control of ECAO added to
air saturated buﬀer alone showed no oxygen consumption, whilst
ECAO added to 2.5 mM b-phenylethylamine in air saturated buﬀer
(the ‘‘classic’’ substrate for the enzyme) led to >90% complete oxygen
consumption in 2 min.
2.2. X-ray crystallography
ECAO crystals were prepared as detailed previously [16]. The crystal
used for data collection was left soaking in a 10:1 ratio of racemic TCP
hemisulfate (Sigma) solution to protein in crystal-stabilising liquor
(1.4 M sodium citrate solution, 0.1 M HEPES buﬀer at pH 7.2) for 20
days to give high occupancy of binding at the ECAO active site [17].
Data were collected at the Daresbury Synchrotron Radiation Source,
station 9.6, on a MAR 300 mm image plate (wavelength 0.87 A; 1 and
1.2 oscillations). The data were processed with MOSFLM/ROTAV-
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using the program TRUNCATE from the CCP4 package of programs
[23,24]. Modelling was performed using O [25], and using the native
ECAO model (resolution 2.0 A; PDB code 1DYU) [18] with the TPQ
side-chains and all active site waters removed as the initial model. All
electron density map calculations and reﬁnement were carried out in
CNS [26], in cycles of positional Powell minimisation and individual
temperature factor reﬁnement, with a maximum likelihood function
target and an overall anisotropic temperature factor correction. Cop-
per ion restraints were weakened by adjustment of the non-bonded
parameters, to enable the copper ion/ligand distances to reﬂect the data
more accurately. Models for the derivatised cofactor with the two TCP
enantiomers were built by using standard geometry to link TPQ with
TCP coordinates derived from the crystal structure of N,N-dimethyl-2-
phenylcyclopropylamine HCl [27]. Dictionaries for CNS and O were
produced with the help of HIC-Up [28] and incorporated ideal ge-
ometries. Reﬁnement was ceased when the largest Fo  Fc peaks ap-
peared to represent noise and the Rfree no longer decreased.3. Results and discussion
3.1. Structure of ECAO complexed with TCP
The structure was solved by diﬀerence Fourier methods and
reﬁned to 2.4 A resolution. The ﬁnal model has good stereo-
chemistry and an R factor¼ 18.5% (Rfree ¼ 22:9%, Table 1).
Structural changes following TCP binding are localised to
the active sites of the homodimeric ECAO. Although exposed
to a racemic mixture of the two TCP enantiomers, the electron
density clearly indicates that only one of the enantiomers, (+)-
TCP (Fig. 1(a)), is covalently bound to the enzyme at high,
although not 100%, occupancy (Fig. 3(a)). Meaningful occu-
pancy reﬁnement was not possible due to the medium resolu-
tion of the data, and the complexity of underlying electron
density from ordered waters, Tyr 381 that ‘‘gates’’ oﬀ the ac-
tive site, and unbound TPQ from the native structure. Exten-
sive modelling with the second enantiomer, ())-TCP, always
led to either the cyclopropyl or phenyl ring lying outside the
electron density (Fig. 3(b)).The residues are tightly packed
through most of the active site, particularly surrounding AspTable 1
Crystallographic data collection and reﬁnement statistics
Space group P212121
Unit cell (A) a ¼ 135:2, b ¼ 166:5,
c ¼ 79:6
Resolution (A) 20–2.4
Number of observed reﬂections 163 856
Number of unique reﬂections 64 108
Completeness (%) overall (ﬁnal shell) 90.1 (80.6)
I=rðIÞ overall (ﬁnal shell) 7.5 (2.9)
Rsym (%) overall (ﬁnal shell)
a 7.5 (25.1)
Wilson B-factor (A2) 36.6
Rcryst (%)
b 18.5
Rfree (%)
c 22.6
Number of atoms 12 909
Average overall B-factor (A2) 30.4
rms bond lengths (A) 0.008
rms bond angles () 1.6
aRsym ¼
P
hklð
P
I ðjIhkl;I  hIhklijÞÞ=
P
hkl;I Ihkl;I, where Ihkl; I is the in-
tensity of an individual reﬂection and hIhkli is the mean intensity of that
reﬂection.
bRcryst ¼
P
hklðjFo;hklj  jFc;hkljÞ=jFo;hklj, where jFo;hklj and jFc;hklj are
the observed and calculated structure factor amplitudes for reﬂections
used during reﬁnement (working set).
cRfree is equivalent to Rcryst but calculated with reﬂections omitted
from the reﬁnement process (test set). The Rfree dataset contained
equivalent reﬂections to a reference Rfree dataset for this crystal form
of ECAO [18].383, the catalytic base, whose hydrophobic environment is
critical for elevating its pKa [15]. There was no evidence in the
electron density that could be associated with a ())-TCP
model, nor that any of the active site residues had an alternate
position that could be accommodating this enantiomer.
In wild-type ECAO, the electron density for the TPQ co-
factor ring shows a high degree of rotational mobility [18]. In
contrast, the electron density for the Schiﬀ base formed at ring
position 5 of the TPQ with the (+)-TCP indicates a well-de-
ﬁned position for the adducted cofactor. Tyr 381, that has been
described as a ‘‘gating’’ residue blocking oﬀ the back of the
active site from solvent in the wild type enzyme [29], has swung
out of the way in the complex to make a side to face ring/ring
interaction with the cyclopropyl ring of (+)-TCP (Fig. 2) [30].
The cyclopropyl ring of (+)-TCP also makes van der Waals
contacts with Val 463 and the catalytic base, Asp 383. The
phenyl ring of the (+)-TCP lies in the narrow substrate entry/
exit channel formed between the 440 amino acid C-terminal
catalytic domain (D4) and a 100 amino acid peripheral do-
main (D3) [17]. It lies in the hydrophobic concave roof of this
channel, making van der Waals contacts with Phe 192, Thr
223, Pro 224, Leu 225 (D3), Val 463, and Gly 464 (D4) and
stacking with the ring of Tyr 387 (D4) (Fig. 2). As observed in
the 2-HP complex with ECAO, the copper ion is sensitive to
the state of the nearby quinone and the equatorial water ligand
distance in the (+)-TCP/ECAO complex lengthens from 2.0 to
4.0 A. The catalytic base, Asp 383, occupies its wild type po-
sition. The lone hydrogen on the tertiary carbon of (+)-TCP,
adjacent to the nitrogen covalently linked to position 5 of the
TPQ ring, is pointing away from Asp 383. Therefore, the ge-
ometry is incorrect for proton abstraction.
3.2. Enantioselectivity of ECAO for TCP
The ())-TCP enantiomer can be modelled so that the phenyl
ring lies in the correct position within the entry channel, al-
though the cyclopropyl ring would sterically clash with Asn
465 (green model, Fig. 3(b)). This would lead to the lone hy-
drogen on the tertiary carbon pointing towards the base for
possible abstraction to yield a ketone product. Within the
conﬁnes of the substrate binding pocket, the groups attached
to a tertiary carbon would be expected to sterically prevent the
amine group of such a molecule from getting close enough to
TPQ to form the Schiﬀ base. However, the ﬁrst report of a
CuAO ketone product has been provided in the enantioselec-
tive oxidation of (R,S)-1-phenyl-2-aminopropane (amphet-
amine) by ECAO and Klebsiella oxytoca CuAO [31]. This
shows that the chemistry for ketone formation can be per-
formed by CuAOs.
To investigate whether the absence of ())-TCP in the active
site of the complex might be due to ())-TCP actually being a
substrate for the enzyme, we looked for evidence, following
initial exposure to the drug, for the consumption of oxygen.
There was no measurable oxygen consumption, as monitored
by an oxygen electrode, upon addition of racemic TCP. This
suggests that ())-TCP does not act as a substrate for ECAO,
and that the enzyme can not rearrange to alleviate the steric
clash between Asn 465 and the cyclopropyl ring of ())-TCP to
allow Schiﬀ base formation with the TPQ.
3.3. Comparison with 2-HP binding
Comparing the TCP and 2-HP complexes with ECAO
(Fig. 2), the structures are startlingly similar, which is
Fig. 3. (a) View of the ﬁnal 2Fo  Fc electron density contoured at 1.0r for the (+)-TCP adducted to the TPQ cofactor. The relationship between the
substrate entry channel and the active site is represented by the molecular surface created by the protein atoms with the adducted TPQ, the copper
ion and its ligands removed. (b) View of the ﬁnal 2Fo  Fc electron density contoured at 1.0r with best ﬁts for a ())-TCP adduct model based on
ﬁtting into the cyclopropyl (pink model) or phenyl ring (green model) electron density, respectively. The molecular surface is shown (deﬁned as in (a))
to aid in visualisation of the steric clashes. Figure produced using SPOCK [39].
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at ﬁrst glance. The majority of the residues lining the substrate
binding pocket are in identical positions and the space occu-
pied by the adducts are superimposable. The ‘‘gate’’ residue,
Tyr 381, takes up a diﬀerent ring orientation in the two com-
plexes, and Tyr 387 is pushed slightly away by the presence of
the extra carbon atom in TCP causing the phenyl ring to
protrude further out of the substrate pocket than the pyridine
ring of 2-HP. The only amino acid whose position is signiﬁ-
cantly diﬀerent between the two is that of the base, Asp 383. In
the TCP complex, the position of Asp 383 is superimposable
with its position in wild type. The presence of nitrogen (N1) in
the numerous hydrazine based inhibitors at this position pro-
vides a hydrogen bonding opportunity for Asp 383 and this
‘‘pulls’’ the residue towards the adduct. In the case of the 2-HP
complex, there is an additional hydrogen bond between Asp
383 and the pyridine ring nitrogen, probably displacing the
position of the base even further.
The proportion of the 2-HP complex is very high in its
crystal structure, as 2-HP is an irreversible inhibitor of CuAOs.
In contrast, TCP is a reversible competitive inhibitor, with a
lM Ki [21]. The electron density for the TCP moiety is weaker
than that of the surrounding protein, and indicates less than100% occupancy, which is consistent with the reversible nature
of the inhibitor.
3.4. Stereospeciﬁcity and substrate preferences of
copper-containing amine oxidases
The ‘‘restricted’’ conformational space available to inhibitor/
substrate in the substrate pocket and entry channel would ex-
plain the strictly controlled stereospeciﬁcity of proton ab-
straction and substrate preferences of CuAOs. Viewed from
above, the substrate binding pocket in ECAO bends 120
around Asn 465 (a conserved residue) and Val 463 ensuring
that the pro-S hydrogen of substrate is pointing towards Asp
383 as deﬁned by the required position of the aromatic ring of
substrate in the curve of the pocket (Fig. 3(a)). Thus, as ob-
served, ECAO always abstracts the pro-S hydrogen from its
substrates. These pockets and entry channels vary signiﬁcantly
in the known crystal structures of CuAOs [16,29,32–34], and
rationally account for the diﬀering stereospeciﬁcities and sub-
strate preferences observed in CuAOs from diﬀerent sources.
3.5. Medical implications
ECAO has between 24% and 25% amino acid sequence
identity with each of the three human CuAO sequences
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all CuAOs [35]. The N-terminal domain (D1) is variable or
absent in diﬀerent CuAOs. The human CuAOs have between
41% and 64% sequence identity with each other in these re-
gions [35]. The observation that only one of the enantiomers
of TCP can bind to ECAO may be considered in the context
that the diﬀering stereospeciﬁcities of proton abstraction are
probably ‘‘ﬁne-tuned’’ by the diﬀerent characteristics of the
substrate binding pockets and entry channels. This leads to
the reasonable supposition that the human CuAOs with their
expected diﬀerent stereospeciﬁcites could selectively bind
diﬀerent enantiomers of TCP and could explain some of the
diﬀerences in side-eﬀects observed from administering
the enantiomers separately, rather than the racemate, in the
treatment of depression. Although it is unlikely that these
drugs could be reﬁned to preclude binding to all human
CuAOs to help alleviate the side-eﬀects involved in their use
as antidepressants acting on ﬂavin-containing amine oxidases,
the exquisite substrate speciﬁcity of the CuAOs could allow
these types of drugs to act as lead compounds in the rational
design of drugs against HuPAO, whose action is linked to the
vascular changes in late diabetic complications and congestive
heart disease. As the human CuAOs are further studied, links
to other diseases are likely to emerge, and the inherent dif-
fering speciﬁcities of these enzymes may allow a new palette
of drugs to be designed from this original class of MAOI
antidepressants to complement other mechanism-based com-
pounds [36,37] or peptides [38].
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